

DAFTAR PUSTAKA

1. Cobo F. Viral hepatitis in imported infectious diseases. Woodhead Publishing. 2014: 213-25.
2. Korsman, Stephen NJ, Zyl GU, Nutt L, Andersson MI, Preiser W. Hepatitis viruses in Virology. Churchill Livingstone. 2012:110–1.
3. Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. *World J Gastroenterol*. 2021;27(26):4004-17.
4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol*. 2017;2:161-76.
5. Global Hepatitis Report 2017. Geneva: World Health Organization. 2017:1-62.
6. Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. *Aliment Pharmacol Ther*. 2019;1–15.
7. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. *Lancet*. 2014;384(9959):2053-63.
8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2095-128.
9. Kemenkes RI. Laporan Hasil Riset Kesehatan Dasar (Riskesdas 2013). Jakarta: Badan Penelitian dan Pengembangan Kesehatan. 2013:1-306.
10. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. *Clinics in liver disease*. 2010;14(1):1-21.
11. PetruzzIELLO A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol*. 2016;22(34):7824-40.
12. Trickey A, Hiebert L, Perfect C, Thomas C, El Kaim JL, Vickerman P, et al. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-

- effectiveness modelling to advance advocacy and strategic planning. *Liver Int.* 2020;40(2):286-97.
13. Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J. Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences. *Int J Mol Sci.* 2022;23(5):1-17.
 14. Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et al. Liver fibrosis: therapeutic targets and advances in drug therapy. *Front. Cell Dev. Biol.* 2021;9(730176):1-18.
 15. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest.* 2005;115(2):209-18.
 16. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nature Reviews Immunology.* 2014;14(3):181-94.
 17. El-Hariri M, Abd El Megid AG, Taha Ali TF, Hassany M. Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. *The Egyptian Journal of Radiology and Nuclear Medicine.* 2017;48(2):329–37.
 18. Del Poggio P, Colombo S. Is transient elastography a useful tool for screening liver disease? *World J Gastroenterol.* 2009;15(12):1409-14.
 19. Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. *PLoS One.* 2012;7(9):1-7.
 20. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol.* 2008;48: 835 - 47.
 21. Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies. *Biomed Pharmacother.* 2019;109:1351-60.
 22. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. *Dig Dis Sci.* 2010;55(9):2624-8.
 23. Dzudzor B, Hammond H, Tachi K, Alisi A, Vento S, Gyasi RK, et al. Serum 25-hydroxyvitamin D and hyaluronic acid levels as markers of fibrosis in patients with chronic liver disease at the main tertiary referral hospital in Ghana: A case-control study design. *Health Sci Rep.* 2023;6(2):1-8.

24. Waldenstrom J, Nystrom K, Nilsson S, Norkrans G, Ydreborg M, Langeland N, et al. The relation of 25-hydroxyvitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. *PLoS One*. 2020;15(8):1-16.
25. Holick MF. Vitamin D Status: Measurement, Interpretation, And Clinical Application. *Annals Of Epidemiology*. 2009;19(2):73-8.
26. Cui A, Zhang T, Xiao P, Fan Z, Wang H, Zhuang Y. Global and regional prevalence of vitamin D deficiency in population-based studies from 2000 to 2022: A pooled analysis of 7.9 million participants. *Front. Nutr*. 2023;10:1-13.
27. Octavius GS, Shakila A, Meliani M, Halim A. Vitamin D deficiency is a public health emergency among Indonesian children and adolescents: a systematic review and meta-analysis of prevalence. *Ann Pediatr Endocrinol Metab*. 2023;28(1):10-19.
28. Stokes CS, Volmer DA, Grünhage F, Lammert F. Vitamin D in chronic liver disease. *Liver Int*. 2013;33(3):338-52.
29. Pop TL, Sirbe C, Bența G, Mititelu A, Grama A. The role of vitamin d and vitamin d binding protein in chronic liver diseases. *Int J Mol Sci*. 2022;23(18):1-18.
30. Gerova DI, Galunska BT, Ivanova II, Kotzev IA, Tchervenkov TG, Balev SP, et al. Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic hepatitis C viral infection. *Scand J Clin Lab Invest*. 2014;74(8):665-72.
31. Naguib R, Fayed A, Abdeen N, Naguib H. Association of serum 25-hydroxyvitamin D₃ levels and insulin resistance with viral load and degree of liver fibrosis in Egyptian chronic HBV patients: a case-control study. *Clin Exp Hepatol*. 2022;8(1):14-20.
32. Petta S, Camma C, Scazzone C, Tripodo C, Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. 2010;51(4):1158–67.
33. Ko BJ, Kim YS, Kim SG, Park JH, Lee SH, Jeong SW, et al. Relationship between 25-Hydroxyvitamin D levels and liver fibrosis as assessed by transient

- elastography in patients with chronic liver disease. *Gut Liver*. 2016;10(5):818-25.
34. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. *Journal of hepatology*. 2011;55(5):1121-31.
 35. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. *World journal of gastroenterology: WJG*. 2011;17(3):283-9.
 36. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. *Nature*. 2005;436:933–8.
 37. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C virus infection: host-virus interaction and mechanisms of viral persistence. *Cells*. 2019;8(4):1-27.
 38. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. *World J Clin Cases*. 2018;6(13):589-99.
 39. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. *Cold Spring Harb Perspect Med*. 2015;5(5):1-12.
 40. Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention. *Infect Dis Clin North Am*. 2019;33(4):1045-1062.
 41. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015;61(1):77-87.
 42. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. *World J Gastroenterol*. 2014;20(30):10395-404.
 43. Soemohardjo S, Gunawan S. Hepatitis B kronik. Dalam: Setiati S, et al. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Jakarta: Interna Publishing. 2015:1963-71.
 44. Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. *Med Microbiol Immunol*. 2015;204(1):5-10.

45. Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-escape hepatitis b virus mutations associated with viral reactivation upon immunosuppression. *Viruses*. 2019;11(9):1-17.
46. Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, et al. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. *World J Gastroenterol*. 2014;20(43):15992-6013.
47. Milito A, Brancaccio M, D'Argenio G, Castellano I. Natural sulfur-containing compounds: an alternative therapeutic strategy against liver fibrosis. *Cells*. 2019;8(11):1-19.
48. Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. *Journal of Hepatology*. 2019;70:294 – 304.
49. Green EW, Kahl L, Jou JH. Systemic Sclerosis and the Liver. *Clin Liver Dis (Hoboken)*. 2021;18(2):76-80.
50. Stabinski L, Reynolds SJ, Ocamo P, Laeyendecker O, Ndyanabo A, Kiggundu V, et al; Rakai Health Sciences Program. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. *Antivir Ther*. 2011;16(3):405-11.
51. Yang M, Ma F, Guan M. Role of steroid hormones in the pathogenesis of nonalcoholic fatty liver disease. *Metabolites*. 2021;11(5):1-16.
52. Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, et al. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. *Clin Exp Med*. 2018;18(3):433-43.
53. Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Miallhes P, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. *Antivir Ther*. 2010;15(7):963-74.
54. Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, et al. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. *Dig Liver Dis*. 2016;48(3):291-7.

55. Brol MJ, Drebber U, Luetkens JA, Odenthal M, Trebicka J. “The pathogenesis of hepatic fibrosis: basic facts and clinical challenges”—assessment of liver fibrosis: a narrative review. *Dig Med Res.* 2022;5(24):1-15.
56. Nan Y, Su H, Lian X, Wu J, Liu S, Chen P, et al Pathogenesis of liver fibrosis and its TCM therapeutic perspectives. *Evid Based Complement Alternat Med.* 2022:1-12.
57. Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic concepts and therapeutic perspectives. *Cells.* 2020;9(4):1-43.
58. Feitelson MA. Pathogenesis of hepatitis B virus associated chronic liver Disease. *Liver Cancer.* 2018;2:13 – 32.
59. Boulahtouf Z, Virzi A, Baumert TF, Verrier ER, Lupberger J. Signaling induced by chronic viral hepatitis: dependence and consequences. *Int. J. Mol. Sci.* 2022;23:1 – 17.
60. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. *Journal of Hepatology.* 2014;61:193 – 95.
61. Kang J, Lee M. Noninvasive diagnostic and prognostic assessment tools for liver fibrosis and cirrhosis in patients with chronic liver disease in liver cirrhosis - update and current challenges. *InTech.* 2017; 35-75.
62. Toosi AE. Liver Fibrosis: Causes and methods of assessment, a review. *Rom J Intern Med.* 2015;53(4):304-14.
63. Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. *Ann Gastroenterol.* 2012;25(3):218-31.
64. Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasoundbased transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. *Liver Transpl.* 2012;18:323—31.
65. Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, et al. Accuracy of transient elastography-FibroScan, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. *Clinics (Sao Paulo).* 2017;72(9):516-25.

66. De Ledingham V, Vergniol J. Transient elastography (FibroScan). *Gastroenterol Clin Biol*. 2008;32:58-67.
67. Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: Liver. *Ultrasound in Medicine & Biology*. 2015;41(5):1161 – 78.
68. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, et al; Grupo para el Estudio de las Hepatitis Viricas de la SAEI. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. *Clin Infect Dis*. 2007;45(8):969-74.
69. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. *World J Gastroenterol*. 2014;20(45):16820-30.
70. Melguizo-Rodríguez L, Costela-Ruiz VJ, García-Recio E, De Luna-Bertos E, Ruiz C, Illescas-Montes R. Role Of vitamin D in the metabolic syndrome. *nutrients*. 2021;13(3): 830 – 47.
71. Bikle DD. Vitamin D: newer concepts of its metabolism and function at the basic and clinical level. *Journal Of The Endocrine Society*. 2020;4(2): 1 - 20
72. Christakos S, Li S, De La Cruz J, Bikle DD. New Developments In Our Understanding of vitamin D metabolism, action and treatment. *Metabolism*. 2019;98:112-20.
73. Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. *J Hepatol*. 2012;57(4):897-909.
74. Pajor SI, Drzewoski J, Sliwinska A. The molecular mechanisms by which vitamin D prevents insulin resistance and associated disorders. *IJMS*. 2020;21(18): 6644-78.
75. Iruzubieta P, Teran A, Crespo J, Fabrega E. Vitamin D deficiency in chronic liver disease. *World J Hepatol*. 2014; 6(12): 901-915
76. Nimitphong H, Holick MF. Vitamin D status and sun exposure in southeast Asia. *Dermatoendocrinol*. 2013;5(1):34-7.
77. Hermawan D, Muhani N, Arisandi S. Blood vitamin D levels in hypercholesterolemic patients. *Jurnal Aisyah: Jurnal Ilmu Kesehatan*. 2022; 7(1):101-6.

78. Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. *Hepatology*. 2012;56(6):2180-7.
79. Acar S, Ozkan B. Vitamin D metabolism in vitamin D. *Intech Open*. 2021; 1-23.
80. Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, et al. Controversies in vitamin D: Summary statement from an international conference. *J Clin Endocrinol Metab*. 2019;104(2):234-40.
81. Pludowski P, Takacs I, Boyanov M, Belaya Z, Diaconu CC, Mokhort T, et al. Clinical practice in the prevention, diagnosis and treatment of vitamin d deficiency: a central and eastern european expert consensus statement. *Nutrients*. 2022;14(7):1-18.
82. Khan MA, Dar HA, Baba MA, Shah AH, Singh B, Shiekh NA. Impact of Vitamin D status in chronic liver disease. *J Clin Exp Hepatol*. 2019;9(5):574-580.
83. Bakke D, Sun J. Ancient Nuclear Receptor VDR With New Functions: Microbiome and Inflammation. *Inflamm Bowel Dis*. 2018;24(6):1149-54.
84. Gong J, Gong H, Liu Y, Tao X, Zhang H. Calcipotriol attenuates liver fibrosis through the inhibition of vitamin D receptor-mediated NF- κ B signaling pathway. *Bioengineered*. 2022;13(2):2658-72.
85. Gascon-Barré M, Demers C, Mirshahi A, Néron S, Zalzal S, Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. *Hepatology*. 2003;37(5):1034-42.
86. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell*. 2013;153(3):601-13.
87. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. *J Endocrinol*. 2009;200(2):207-21.
88. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker

- expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. *Gut*. 2011;60(12):1728-37.
89. Behera MK, Swain SN, Abhilash VB, Shukla SK, Dixit VK. Relationship of serum vitamin D with hepatic fibrosis in patients with chronic hepatitis C. *Int J Res Med Sci*. 2020;8(10):3618-23.
90. Shah I, Ahmad W, Islam F, Hadi MH, Mahmood J, Kashif M. Vitamin D deficiency in patients with chronic liver disease: a clinical study at a tertiary care hospital. *PJMHS*. 2022;16(12): 740-1.
91. Hassani MK. Role of vitamin D as protective agent against induced liver damage in male rats. *archives of razi institute*. 2021;76(6):1815-22.
92. Banerjee A, Athalye S, Khargekar N, Shingade P, Madkaikar M. Chronic hepatitis B and related liver diseases are associated with reduced 25-hydroxy-vitamin D levels: a systematic review and metaanalysis. *Biomedicines*. 2023; 11(135)1-17.
93. Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, et al; HIV-NAT125 study team. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. *J Gastroenterol Hepatol*. 2014;29(9):1706-14.
94. Nah EH, Cho S, Kim S, Chu J, Kwon E, Cho HI. Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. *BMJ Open*. 2021;11: 1-10.
95. Ahmed F, Paul P, Hasan R, Habib R, Gain G, Kabir MA. The concentration of 25-Hydroxyvitamin D in chronic liver disease and its' correlation with severity. *Bangladesh Medical Journal*. 2021;49(3), 35–42.
96. Kumar D, Khan MU, Kashif SM, Shaikh MA, Nawaz Z, Shaikh U. Association of vitamin D deficiency with hepatitis B and C virus infection. *J. Pharm. Res. Int*. 2021;33(25A):1-6.
97. Cooper KM, Delk M, Devuni D, Sarkar M. Sex differences in chronic liver disease and benign liver lesions. *JHEP Rep*. 2023;5(11):1-12.

98. Liu TW, Huang CF, Yeh ML, Yeh ML, Tsai PC, Jang TY, et al. Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. *BMJ Open Gastro*. 2020;7:1-10.
99. Gopalakrishna H, Fashanu OE, Nair GB, Ravendhran N. Association between body mass index and liver stiffness measurement using transient elastography in patients with non-alcoholic fatty liver disease in a hepatology clinic: a cross sectional study. *Transl Gastroenterol Hepatol*. 2023;8:1-10.
100. Rao H, Shang J, Xie Q, Lan J, Gao P, Shi J, et al. Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis. *iLIVER*. 2022;1(3):145-53.
101. Erem AS, Razzaque MS. Vitamin D-independent benefits of safe sunlight exposure. *The Journal of Steroid Biochemistry and Molecular Biology*. 2021;213: 1 – 9.
102. Husna K, Widajanti N, Sumarmi S, Firdaus H. Hubungan antara skor paparan matahari dan asupan vitamin D dengan kadar 25(OH)D serum pada wanita usia lanjut. *JPDI*. 2021;8(2):63 – 71.
103. Gorman S, Black LJ, Feelisch M, Hart PH, Weller R. Can skin exposure to sunlight prevent liver inflammation? *Nutrients*. 2015;7(5):3219-39.
104. Azevedo LA, Matte U, Silveira TR, Bonfanti JW, Bruch JP, Álvares-da-Silva MR. Effect of vitamin D serum levels and gc gene polymorphisms in liver fibrosis due to chronic hepatitis C. *Ann Hepatol*. 2017;16(5):742-8.
105. Hashemi SJ, Parsi A, Hajiani E, Masjedizadeh A, Shayesteh A. Relationship Between 25-HydroxyVitamin D level and liver stiffness in patients with chronic hepatitis B using transient elastography. *Hepat Mon*. 2020; 20(7):1-5.
106. Amanzada A, Goralczyk AD, Moriconi F, van Thiel DH, Ramadori G, Mihm S. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. *Journal of Medical Virology*. 2013;85:1534–41.
107. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. *J Hepatol*. 2011;54(5):887-93.

108. Hoan NX, Khuyen N, Binh MT, Giang DP, Van Tong H, Hoan PQ, et al. Association of vitamin D deficiency with hepatitis B virus - related liver diseases. *BMC Infect Dis.* 2016;16(1):1-8
109. Price JK, Srivastava R, Bai C, Diao G, Gerber LH, Younossi ZM. Comparison of activity level among patients with chronic liver disease. *Disabil Rehabil.* 2013;35(11):907-12.
110. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int.* 2009;20(11):1807-20.
111. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. *J Hepatol.* 2011;55(4):756-61.
112. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.
113. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Eloranta JJ, et al; Swiss Hepatitis C Cohort Study Group. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1H1) variants on fibrosis progression rate in HCV patients. *Liver Int.* 2012;32(4):635-43